Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (51): 9667-9670.doi: 10.3969/j.issn.1673-8225.2011.51.040

Previous Articles     Next Articles

Biological coating materials of intravascular stent surface and intravascular restenosis

Xu Hai-feng   

  1. Department of Cardiology, Shenzhou Hospital Affiliated to Shenyang Medical College, Shenyang  110002, Liaoning Province, China
  • Received:2011-10-10 Revised:2011-11-07 Online:2011-12-17 Published:2011-12-17
  • About author:Xu Hai-feng, Attending physician, Department of Cardiology, Shenzhou Hospital Affiliated to Shenyang Medical College, Shenyang 110002, Liaoning Province, China shenymengf@126.com

Abstract:

BACKGROUND: Cardiopathy is one of the most important causes of disease which threaten human health. Every year, about  15 million patients with coronary heart disease around the world need percutaneous puncture coronary angioplasty therapy. But about 10% of them develop acute and subacute artery occlusion; 20% to 50% of them develop intravascular restenosis in six months. Restenosis has already become one of the most critical factors that restrict the development of percutaneous puncture coronary angioplasty.
OBJECTIVE: To discuss the long-term clinical effects of drug-eluting stent in stent restenosis.
METHODS: An online search of Chinese Journal Full-text Database was performed for articles with the key words of “drug-eluting stent”, “obstruction” and “restenosis”. Meta analysis and repetitive studies were excluded. A total of 25 articles were retained, involving the progress of stent placement, the prevention of stent stenosis and the effects of different stent types, materials on recanalizing rate and recanalizing time.
RESULTS AND CONCLUSION: Using drug-loading technology and controlled drug release technology, the drug-eluting stent mechanically support the lesion vessels; in the mean time, drugs that inhibit the proliferation of vascular smooth muscle cells release slowly from the stent surface, act on the vascular walls touching the stent. Thereby, problems of elastic recoil and intima hyperplasia are solved. With the improvement and innovation of interventional equipments for coronary, drug-eluting stent technology is maturing and developing. The design concept of the emerging drug-eluting stent technology is based on drug screening and controlled drug release system. It is believed that drug-eluting stents will be used in a wide range of complex vascular lesions (especially venous diseases and vascular injuries) and other organ diseases.

CLC Number: